Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing the combination of teclistamab and mezigdomide to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment.
The purpose of this study is to assess the feasibility of a new approach to treat people with T4 breast cancer who have already received chemotherapy. T4 breast cancer occurs when the cancer has grown beyond normal breast tissue and into the chest wall or skin or has become swollen and causes pain. Doctors normally treat T4 breast cancer with chemotherapy followed by mastectomy and removal of underarm (axillary) lymph nodes. After mastectomy, patients normally receive radiation therapy and then have breast reconstruction surgery many months to years after completing radiotherapy.
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Radiation therapy uses radiation to kill cancer cells and shrink tumors. Chemotherapy stops the growth of cancer cells, either by killing the cells or stopping them from dividing. However, this standard combination may cause severe side effects because it is given over 7 weeks. These side effects include sores in the mouth and gut, sore throat, and changes in taste.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
In this study, researchers want to find out how different amounts of aerobic training might improve cardiorespiratory fitness in people while they are treated for breast cancer. Cardiorespiratory fitness is important for the health of people receiving treatment for breast cancer. Aerobic exercise stimulates and strengthens the heart and lungs and improves how the body uses oxygen.
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In this study, researchers are seeking to find the highest dose of the investigational drug BGB-16673 that can be given safely in people with lymphoma and other types of B cell cancers that have come back or continued to grow despite prior treatment. BGB-16673 degrades a protein called BTK, which helps B cells live and grow. By degrading BTK, BGB-16673 may stop or slow the growth and activity of B cells, which could lead to improvement in the symptoms associated with B cell cancers. BGB-16673 is taken orally (by mouth).
